Lepromatous leprosy in a patient with psoriasis receiving biologic therapy
PDF (Portuguese (Brazil))

Keywords

Leprosy
Mycobacterium leprae
Adalimumab
Tumor necrosis factor-alpha
Immunosuppression

How to Cite

Lepromatous leprosy in a patient with psoriasis receiving biologic therapy. (2026). Revista Eletrônica Acervo Médico, 26, e25580. https://doi.org/10.25248/reamed.e25580.2026

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: To report a case of multibacillary lepromatous leprosy in a patient with psoriasis and psoriatic arthritis receiving adalimumab, highlighting the clinical presentation, diagnostic investigation and therapeutic evolution. Case report: A 73-year-old man with systemic arterial hypertension, diabetes mellitus, benign prostatic hyperplasia, psoriasis and psoriatic arthritis receiving adalimumab developed asymptomatic erythematous nodular skin lesions for approximately seven months. The lesions initially appeared on the chest and subsequently spread to the face, abdomen, back and limbs. Dermatological examination showed multiple erythematous-violaceous nodules, some scaly, and infiltrated plaques. Skin biopsy demonstrated preservation of the Grenz zone, a dense lymphohistiocytic infiltrate and a high bacillary burden, reported as ++++, compatible with multibacillary lepromatous leprosy. Adalimumab was discontinued and uniform multidrug therapy was initiated. After five months, clinical improvement was observed, with reduction of the infiltrative and erythematous components and persistence of residual lesions. Final considerations: Leprosy should be considered in the differential diagnosis of infiltrative dermatoses in patients receiving anti-TNF-α therapy, particularly in endemic areas. The temporal association does not establish causality with adalimumab, but supports clinical surveillance during immunomodulation.

PDF (Portuguese (Brazil))

References

1. ALREHAILI J. Leprosy classification, clinical features, epidemiology, and host immunological responses: failure of eradication in 2023. Cureus, 2023; 15(9): e44767.

2. BARROSO DH, et al. Leprosy detection rate in patients under immunosuppression for the treatment of dermatological, rheumatological, and gastroenterological diseases: a systematic review of the literature and meta-analysis. BMC Infectious Diseases, 2021; 21(1): 347.

3. BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasília: Ministério da Saúde, 2022.

4. BRÜGGER LMO, et al. What happens when Schwann cells are exposed to Mycobacterium leprae: a systematic review. IBRO Neuroscience Reports, 2023; 15: 11-16.

5. COGEN AL, et al. Biologics in leprosy: a systematic review and case report. American Journal of Tropical Medicine and Hygiene, 2020; 102(5): 1131-1136.

6. CRUZ VA, et al. New insights at the interface between leprosy and immune-mediated rheumatic diseases. Frontiers in Medicine, 2023; 10: 1239775.

7. DEWI DAR, et al. Immunopathogenesis of type 1 and type 2 leprosy reaction: an update review. Cureus, 2023; 15(11): e49155.

8. FREITAS DS, et al. Lepromatous leprosy associated with the use of anti-TNF alpha therapy: case report. Revista Brasileira de Reumatologia, 2010; 50(3): 333-339.

9. FROES JUNIOR LAR, et al. Leprosy: clinical and immunopathological characteristics. Anais Brasileiros de Dermatologia, 2022; 97(3): 338-347.

10. FROES JUNIOR LAR, et al. Leprosy in the 21st century: a comprehensive review of immunological mechanisms, diagnosis, and treatment. Revista do Instituto de Medicina Tropical de São Paulo, 2025; 67: e74.

11. GILMORE A, et al. Leprosy (Hansen's disease): an update and review. Missouri Medicine, 2023; 120(1): 39-44.

12. HUANG CY, et al. An update of the diagnosis, treatment, and prevention of leprosy: a narrative review. Medicine, 2024; 103(34): e39006.

13. LE PH, et al. Pathogenesis, clinical considerations, and treatments: a narrative review on leprosy. Cureus, 2023; 15(12): e49954.

14. MASSONE C, et al. Histopathology of the lepromatous skin biopsy. Clinics in Dermatology, 2015; 33(1): 38-45.

15. MENDES AFM, et al. Case report: a case series of immunobiological therapy (anti-TNF-α) for patients with erythema nodosum leprosum. Frontiers in Medicine, 2022; 9: 879527.

16. OBERSTEIN EM, et al. Type I reaction of Hansen's disease with exposure to adalimumab: a case report. Arthritis and Rheumatism, 2008; 59(7): 1040-1043.

17. ROMERO CP, et al. Accuracy of rapid point-of-care serological tests for leprosy diagnosis: a systematic review and meta-analysis. Memórias do Instituto Oswaldo Cruz, 2022; 117: e220317.

18. SILVA MJA, et al. An update on leprosy immunopathogenesis: systematic review. Frontiers in Immunology, 2024; 15: 1416177.

19. SONG S, et al. Diagnosis of new leprosy patients through various histological findings according to biopsy sites. Annals of Dermatology, 2022; 34(6): 487-489.

20. WORLD HEALTH ORGANIZATION. Guidelines for the diagnosis, treatment and prevention of leprosy. New Delhi: WHO Regional Office for South-East Asia, 2018.

21. WORLD HEALTH ORGANIZATION. Global leprosy (Hansen disease) update, 2024: beyond zero cases - what elimination of leprosy really means. Weekly Epidemiological Record, 2025; 100(37): 365-384.